within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA06_RosuvastatinAndEzetimibe;

model RosuvastatinAndEzetimibe
  extends Pharmacolibrary.Drugs.ATC.C.C10BA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C10BA06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rosuvastatin and ezetimibe is a fixed-dose combination drug used to manage hypercholesterolemia and mixed dyslipidemia. Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that reduces cholesterol synthesis, while ezetimibe reduces cholesterol absorption in the intestine. The combination is approved for use in adults to lower LDL cholesterol when statin monotherapy is insufficient.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects after oral administration of fixed-dose rosuvastatin 10 mg and ezetimibe 10 mg, based on public pharmacokinetic data for each component; no published PK model for the fixed combination was identified.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li><li><p>Kim, CH, et al., &amp; Shin, D (2021). Pharmacokinetic Interaction Between Telmisartan and Rosuvastatin/Ezetimibe After Multiple Oral Administration in Healthy Subjects. <i>Advances in therapy</i> 38(2) 1094–1105. DOI:<a href=\"https://doi.org/10.1007/s12325-020-01592-8\">10.1007/s12325-020-01592-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33326064/\">https://pubmed.ncbi.nlm.nih.gov/33326064</a></p></li><li><p>Kim, CH, et al., &amp; Shin, D (2017). Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. <i>Drug design, development and therapy</i> 11 3461–3469. DOI:<a href=\"https://doi.org/10.2147/DDDT.S146863\">10.2147/DDDT.S146863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29255347/\">https://pubmed.ncbi.nlm.nih.gov/29255347</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RosuvastatinAndEzetimibe;
